In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase
- 26 September 2005
- journal article
- research article
- Published by Wiley in Biotechnology & Bioengineering
- Vol. 92 (7), 831-842
- https://doi.org/10.1002/bit.20658
Abstract
The Fc effector functions of immunoglobulin G (IgG) antibodies are in part determined by structural features of carbohydrates linked to each of the paired gamma heavy chains in the antibody constant domain (CH2). One glycoform that has been shown to be advantageous is G2, where both arms of complex bi‐antennary N‐glycans terminate in galactose. In vitro treatment with glycosyltransferases can remodel heterogeneous IgG glycoforms, enabling preparation of IgG molecules with homogeneous glycan chains. Here we describe optimization of conditions for use of a soluble recombinant galactosyltransferase in vitro to remodel glycans of human serum IgG, and we demonstrate a scaled‐up reaction in which >98% of neutral glycans attached to 1 kg IgG are converted to the G2 glycoform. Removal of glycosylation reagents from the product is achieved in one step by affinity chromatography on immobilized Protein A.Keywords
This publication has 54 references indexed in Scilit:
- Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technologyGlycobiology, 2004
- Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune DiseasesAnnual Review of Medicine, 2004
- Recombinant antibodies for cancer diagnosis and therapyExpert Opinion on Biological Therapy, 2003
- Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural IntegrityJournal of Molecular Biology, 2003
- The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular CytotoxicityJournal of Biological Chemistry, 2003
- Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular ToxicityJournal of Biological Chemistry, 2002
- Recognition of IgG by Fcγ ReceptorPublished by Elsevier ,2001
- Antibody-Targeted Immunotherapy for Treatment of MalignancyAnnual Review of Medicine, 2001
- Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgGNature, 1985
- Some Kinetic Properties of Human-Milk Galactosyl TransferaseEuropean Journal of Biochemistry, 1974